ARROWHEAD PHARMACEUTICALS INC
For the period ended Jan 28, 2025. Filed Jan 29, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jan 28, 2025 · Filed Jan 29, 2025
Contents
Board Composition and Nominating Process
The Nomination Committee of the Board annually considers the size, composition and needs of the Board and, as appropriate, recommends the nominees for directors to the Board for approval. The Nomination Committee considers and evaluates suggestions from many sources regarding possible candidates for directors. Below are general criteria for the evaluation of current and proposed directors:
The highest ethical character and shared values with our Code of Corporate Conduct
Reputation, both personal and professional, consistent with our image and reputation
Accomplishment within a candidate’s field, with superior credentials and recognition
Relevant expertise and experience and the ability to offer advice and guidance to the Chief Executive Officer based on such expertise and experience
Independence, without the appearance of any conflict in serving as a Director, and independence of any particular constituency with the ability to represent all stockholders
Ability to exercise sound business judgment
Diversity, reflecting differences in skills, regional and industry experience, backgrounds, ages, and other unique characteristics, such as race, gender and ethnicity
The Nomination Committee considers the mix of skills and experience among current and prospective directors with a goal of assembling a Board with complementary skills for the benefit of the Company. Listed below are selected key contributions of each current Board member. The table is not intended to be an exhaustive summary of all the contributions of each Board member.
| Expertise | Given | Perry | Anzalone | Ferrari | Olukotun | Vakiener | Waddill | Lu | Ingram |
|---|---|---|---|---|---|---|---|---|---|
| Biopharma Research& Development | X | X | X | X | X | X | X | X | X |
| Healthcare | X | X | X | X | X | X | X | X | X |
| Drug Development | X | X | X | X | X | X | X | ||
| Executive Leadership | X | X | X | X | X | X | X | X | X |
| Public CompanyGovernance | X | X | X | X | X | X | X | X | X |
| Accounting/Audit | X | X | X | X | |||||
| Capital Markets | X | X | X | X | X | X | |||
| Commercial | X | X | X | X | X | ||||
Board Diversity
The Nomination Committee believes that the Board should represent a diverse mix of skills, regional and industry experience, backgrounds, ages, and other unique characteristics, such as race, gender, and ethnicity. In furtherance of this goal, the Committee is committed to actively seeking out highly qualified diverse candidates (including women and minority candidates) to include in the pool from which Board nominees are chosen.
| Board Diversity Matrix (As of January 28, 2025) | ||||
|---|---|---|---|---|
| Total Number of Directors | #8 | |||
| Female | Male | Non-Binary | Did Not Disclose Gender | |
| Part I: Gender Identity | ||||
| Directors | 2 | 6 | 0 | 0 |
| Part II: Demographic Background | ||||
| African American or Black | 0 | 1 | 0 | 0 |
| Alaskan Native or Native American | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 |
| Hispanic or Latinx | 0 | 0 | 0 | 0 |
| Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 0 |
| White | 1 | 5 | 0 | 0 |
| Two or More Races or Ethnicities | 0 | 0 | 0 | 0 |
| LGBTQ+ | 0 | |||
| Did Not Disclose Demographic Background | 0 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.